FERRER

Foundation

In 1959 Ferrer began his career under the presidency of Carlos Ferrer Salat

(1931-1998).

Consolidation

During the 1960s, Ferrer became one of the most important national companies in the Spanish market.

Internationalization

Ferrer begins its international expansion with acquisitions in Germany and the establishment of subsidiaries in Latin America.

Integration

Full vertical integration. Creation of new divisions, between 1976 and 1978, to enter the manufacture and commercialization of fine chemicals.

Innovation

Inauguration of a new R&D center in Barcelona (1977). Consolidation of Ferrer's historical commitment to research and development of innovative pharmaceutical products.

Commitment

Implementation of GMP standards in all Ferrer factories, placing the company at the forefront of the sector at a technological level.

Diversification

Some acquisitions and the expansion of Measure Ferrer and Ferrer Alimentación further strengthen the company's presence in the food additives and fine chemicals sectors.

Developing

Ferrer inaugurates the hospital business unit as a strategic area for the future, focusing on oncology, intensive medicine and pain management.

Achievements

Since 2000, Ferrer has been recognized as one of the best national pharmaceutical companies based on R&D.

Expansion

The new subsidiaries, joint ventures and acquisitions reinforce Ferrer's presence in southern Europe and throughout Latin America.

Ambit

Ferrer operates in the different segments of the health system. New acquisitions in prescription, OTC and animal nutrition bring critical mass to the company. Personalized medicine and advanced technological platforms allow you to start an innovative path.

Sustainability

New logistics center and factory expansion with LEED certification for sustainable construction. Launch of the Our planet, Our Life sustainability strategy.

Specialization

Under the mandate of the new CEO, Mario Rovirosa, Ferrer enters a phase of renewal, focusing efforts on the area of ​​prescription, specialized, proprietary and incremental innovation preparations.